Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases.

Journal Article (Journal Article)


Particle Replication in Nonwetting Templates (PRINT(®)) PLGA nanoparticles of docetaxel and acid-labile C2-dimethyl-Si-Docetaxel were evaluated with small molecule docetaxel as treatments for non-small-cell lung cancer brain metastases.

Materials & methods

Pharmacokinetics, survival, tumor growth and mice weight change were efficacy measures against intracranial A549 tumors in nude mice. Treatments were administered by intravenous injection.


Intracranial tumor concentrations of PRINT-docetaxel and PRINT-C2-docetaxel were 13- and sevenfold greater, respectively, than SM-docetaxel. C2-docetaxel conversion to docetaxel was threefold higher in intracranial tumor as compared with nontumor tissues. PRINT-C2-docetaxel increased median survival by 35% with less toxicity as compared with other treatments.


The decreased toxicity of the PRINT-C2-docetaxel improved treatment efficacy against non-small-cell lung cancer brain metastasis.

Full Text

Duke Authors

Cited Authors

  • Sambade, M; Deal, A; Schorzman, A; Luft, JC; Bowerman, C; Chu, K; Karginova, O; Swearingen, AV; Zamboni, W; DeSimone, J; Anders, CK

Published Date

  • August 2016

Published In

Volume / Issue

  • 11 / 15

Start / End Page

  • 1947 - 1955

PubMed ID

  • 27456556

Pubmed Central ID

  • PMC4996152

Electronic International Standard Serial Number (EISSN)

  • 1748-6963

International Standard Serial Number (ISSN)

  • 1743-5889

Digital Object Identifier (DOI)

  • 10.2217/nnm-2016-0147


  • eng